UroGen Pharma面临诉讼,指控对UroGen Pharma关于UGN-102的EnviSION研究提出误导性指控。 UroGen Pharma faces lawsuit over alleged misleading claims about its ENVISION study for UGN-102.

UroGen Pharma正面临一项集体诉讼,指控其错误陈述和隐瞒其UGN-102药物EnVISION临床研究。 UroGen Pharma is facing a class-action lawsuit alleging false statements and concealment about its ENVISION clinical study for the drug UGN-102. 该诉讼主张该研究缺乏一个控制小组,因此难以证明该药物的有效性,并增加了林业发展局拒绝批准的风险。 The lawsuit claims the study lacked a control group, making it hard to prove the drug's effectiveness and increasing the risk of FDA approval denial. 在2023年7月27日至2025年5月15日期间购买UroGen证券的投资者可在2025年7月28日前加入诉讼。 Investors who bought UroGen securities between July 27, 2023, and May 15, 2025, may join the lawsuit by July 28, 2025.